Arthrocare considers future
This article was originally published in The Gray Sheet
Executive Summary
ArthroCare, maker of minimally invasive Coblation devices that use low-temperature radiofrequency energy to gently dissolve soft tissue, said March 3 that its Board of Directors is evaluating financial and strategic alternatives, including recapitalization, stock repurchase, sale of assets or strategic business combinations. The board's decision is based on its belief that ArthroCare's current stock price - which closed March 3 at $43 - does not reflect the fundamental value of the business